PGFX Patent Holdings Acquires Orogen Biosciences Assets and Resurrects Hair Growth and Restoration Patent
PGFX Patent Holdings’ asset acquisition of Orogen Biosciences, Inc., proprietary methods, devices, and intellectual property paves the way for advancements in regenerative medicine. The asset transfer enables PGFX, which operates as Heritage Biosciences, LLC, to heighten its efforts toward tissue repair, regeneration, and revascularization. By acquiring the patents, Heritage strengthens its stance as a leader in point of care and allogeneic regenerative therapies for humans, as well as animals.
The processing of platelet rich plasma with growth factors, proteins, cytokines, and adhesion molecules was pioneered by Orogen. Heritage’s acquisition of these devices and patents allows physicians to utilize their patients’ growth factors and adhesion molecules as part of their healing program. Medical research and opinions reflect increasing evidence that growth factors, scaffolds, and adhesion molecules enhance the healing process in various medical applications. These technologies include the (OPC™) device, which allows physicians to process autologous blood plasma at the point of care to deliver concentrated platelet poor plasma (cPPP) used as an autologous ECM (Extracellular Matrix/Scaffold) scaffold to be used in conjunction with the physician’s choice of Cellular and or Growth Factor Concentrate.
The Negative or Sub-Atmospheric pressure extraction process allows for the most efficacious growth factor composition available in the regenerative field of medicine. The patented process’s and devices (ACE™) produce an enriched preparation of natural state growth factors in an acellular form (CRP™). This unique composition discards excess water, cells, cellular debris and unwanted inflammatory components, producing the purest and most enriched growth factor technology at the point of care. This patent, No. 8,734,854, “Process for Removing Growth Factors from Platelets, allows rapid penetration to existing emerging markets with substantial protective barriers to entry. This includes Negative Pressure Wound Therapy (NPWT) which is approximately a $4.2 Billion market.
Additionally, Heritage has acquired proprietary methods and underlying intellectual property for delivering an allogeneic, acellular growth factor enriched product to the veterinary market. This product is lyophilized, sustaining growth factors, proteins and other specific peptides in a state of suspended animation with extended shelf life of plus one year. Based on current, short and long-term success of these products treating musculoskeletal tissue repair in both Equine and Canine application, Heritage is positioned to penetrate the veterinary market, which is leading human efforts into the emerging market of regenerative medicine.
Heritage is seeking to provide multilateral licensing to strategic partners domestically and abroad. Intellectual Property (IP) has become an important source of competitive advantage at micro levels in biotechnology companies. The importance of IP management will allow for exponential growth of product and economic framework. Heritage looks forward to licensing cooperative relationships with strategic partners. We believe this is a unique opportunity for PGFX Patent Holdings to diversify into the regenerative medicine space.
Although a number of companies approached Orogen about acquiring the intellectual property, Orogen felt confident that Heritage had the vision to create significant value in the regenerative medicine space.
PGFX/Heritage Bioscience was subsequently successful in the resurrection of Skin Treatment for Promoting Hair Growth, Patent No. 9,227,089 B1. Originally invented by Robert Brandt and Joseph Greco, the patent (issued on January 9, 2016) places Heritage at the forefront in multiple platforms of regenerative medicine and growth. Heritage is actively seeking marketers with the strategic and financial capabilities to market their hair growth and restoration technology through PRP hair treatments.